1. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery
   Arun Radhakrishnan et al, 2020, The Pharmacogenomics Journal CrossRef
2. Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations
   Camila Farinango et al, 2022, Journal of Personalized Medicine CrossRef
3. Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
   Marina Borro et al, 2017, Oncotarget CrossRef
4. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
   Dan Liu et al, 2017, BMC Cancer CrossRef
5. Vistogard (Uridine Triacetate)
   Patricia Anne O’Malley, 2016, Clinical Nurse Specialist CrossRef
6. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer
   Pashtoon Murtaza Kasi et al, 2019, Technology in Cancer Research & Treatment CrossRef
7. Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
   Andrea Botticelli et al, 2016, PLOS ONE CrossRef
8. Toxic and Adverse Effects of Chemotherapy with 5-Fluoropyrimidine Drugs. Could Dihydropyrimidine Dehydrogenase Enzyme Screening Serve as a Prerequisite to Successful Chemotherapy?
   Velko T. Minchev, 2020, Journal of Biomedical and Clinical Research CrossRef